Ashish Kamat, Professor and Director of Urologic Oncology Fellowship at MD Anderson Cancer Center, shared a post on X about a paper he co-authored published in Human Pathology:
“Our study on molecular profiling of 99 cases of micropapillary urothelial carcinoma (MPUC):
Most common mutations: TP53, TERT, ARID1A, ERBB2
ERBB2 alterations in 24%: Amplifications, Missense mutations (most common: p.S310F)
Only ERBB2 amplifications associated with: HER2 overexpression, significantly worse overall survival (p=0.043)
MPUC tumors are luminal in origin and share features with conventional UC – but with distinct biology and clinical behavior.
Implication: Molecular profiling should be standard for MPUC. ERBB2 amplifications – not just mutations -may identify patients who need intensified or targeted therapy.”
Title: Molecular profile of micropapillary urothelial carcinoma of the urinary bladder: An analysis of 99 cases by next-generation sequencing
Authors: Yuan Shen, Lan Zheng, Jianping Zhao, Yishan Wang, Hui Chen, Sinchita Roy-Chowdhuri, Ashish M. Kamat, Omar Alhalabi, Jianjun Gao, Arlene Siefker-Radtke, Peng Wei, Donna E. Hansel, Bogdan Czerniak, Charles C. Guo
You can read the Full Article in Human Pathology.
More posts featuring Ashish Kamat.
